| Quote
: |
伍静,李为,刘华,王宇龙,钟佳,薛培森.扶正口服液联合rhTPO治疗含铂双药方案化疗后血小板减少症的临床观察[J].湖南中医药大学学报英文版,2023,43(4):638-642.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 1159times Download 763times |
| 扶正口服液联合rhTPO治疗含铂双药方案化疗后血小板减少症的临床观察 |
| 伍静,李为,刘华,王宇龙,钟佳,薛培森 |
| (湖南中医药大学第一附属医院, 湖南 长沙 410007;湖南中医药大学, 湖南 长沙 410208) |
| 摘要: |
| 目的 观察扶正口服液联合重组人血小板生成素（recombinan human thrombopoietin, rhTPO）治疗含铂双药方案化疗后血小板减少症（chemotherapy induced thrombocytopenia, CIT）的临床疗效。方法 将医院收治的61例使用含铂双药方案化疗所致CIT患者随机分为治疗组（31例）和对照组（30例）。对照组患者皮下注射rhTPO，15 000 U，1次/d；治疗组在对照组基础上加用扶正口服液，50 mL/次，口服，每天3次；饭后服用，治疗时间均为2周。对比2组的临床疗效，观察2组治疗前后血小板（platelet, PLT）计数情况、CIT分级情况、PLT回升例数、rhTPO使用时间、卡氏（Karnofsky, KPS）评分及中医证候评分、不良反应。结果 治疗后，治疗组的有效率优于对照组（P＜0.05）；2组PLT计数均较治疗前上升，且治疗组高于对照组（P＜0.05）；2组CIT分级情况较治疗前均减低（P＜0.05），且治疗组低于对照组（P＜0.05）；治疗组PLT回升例数高于对照组（P＜0.05）；治疗组使用rhTPO的天数少于对照组（P＜0.05）；2组的KPS评分与中医证候评分均较治疗前改善（P＜0.05），且治疗组优于对照组（P＜0.05）。治疗过程中，2组不良反应发生率差异无统计学意义（P＞0.05）。结论 扶正口服液联合rhTPO在改善CIT方面优于rhTPO单药使用，两者联合能更有效地升高PLT计数，同时缩短rhTPO使用时间、改善患者生活质量。 |
| 关键词: 扶正口服液 化疗后血小板减少症 中医药 含铂双药方案 骨髓抑制 铂类 |
| DOI：10.3969/j.issn.1674-070X.2023.04.010 |
| Received:September 14, 2022 |
| 基金项目:湖南省自然科学基金项目（2021JJ30523）；湖南省中医肿瘤临床医学研究中心（2021SK4023）。 |
|
| Clinical observation of Fuzheng Oral Liquid combined with rhTPO in treating platinum-based doublet chemotherapy induced thrombocytopenia |
| WU Jing,LI Wei,LIU Hua,WANG Yulong,ZHONG Jia,XUE Peisen |
| (The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To observe the clinical efficacy of Fuzheng Oral Liquid combined with recombinan human thrombopoietin (rhTPO) in treating chemotherapy induced thrombocytopenia (CIT) after platinum-based doublet chemotherapy.Methods A total of 61 patients with CIT induced by platinum-based doublet chemotherapy were randomly divided into treatment group (n=31) and control group (n=30). The control group received subcutaneous injection of rhTPO (15 000 U, once a day), while the treatment group received oral administration of Fuzheng Oral Liquid (50 mL) after meals 3 times per day combined with the subcutaneous injection of rhTPO (15 000 U) once per day. Both groups were treated for 2 weeks. The curative efficacy were compared between the two groups, and the platelet (PLT) count, CIT grades, number of platelet recovery cases, duration of rhTPO injection, Karnofsky (KPS), and TCM pattern score, as well as the adverse reactions were observed in both groups before and after treatment.Results After treatment, the effective rate of treatment group was higher than that of control group (P<0.05); the PLT count in both groups was higher than that before treatment and the increase in treatment group was higher than that in control group (P<0.05); the CIT grades in both groups were lower (P<0.05), and the decrease in treatment group was sharper than that in control group (P<0.05); the number of platelet recovery cases in treatment group was higher than that of control group (P<0.05); the duration of rhTPO injection in the treatment group was shorter than that in control group (P<0.05); the scores of TCM pattern and KPS of two groups were both improved compared with those before treatment, and the improvement in the treatment group was better than that in the control group (P<0.05). During the treatment, there was no statistical significance in the incidence of adverse reactions between two groups (P>0.05).Conclusion Fuzheng Oral Liquid combined with rhTPO is superior to rhTPO monotherapy in curing CIT. Moreover, the combination of the two can more effectively increase PLT count, shorten the time to administer rhTPO, and improve the life quality of patients. |
| Key words: Fuzheng Oral Liquid chemotherapy induced thrombocytopenia Chinese medicine platinum-based doublet chemotherapy myelosuppression platinum |
|
二维码（扫一下试试看！） |
|
|
|
|
